Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

DLBCL, Diffused Large B Cell Lymphoma: early-phase trial registry

1 of 1 indexed DLBCL, Diffused Large B Cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

DLBCL, Diffused Large B Cell Lymphoma: 1 US clinical trial tracked, 1 recruiting.

DLBCL, Diffused Large B Cell Lymphoma is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Poseida Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition dlbcl-diffused-large-b-cell-lymphoma

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

DLBCL, Diffused Large B (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near DLBCL, Diffused Large B Cell Lymphoma

DLBCL, Diffused Large B Cell Lymphoma lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for DLBCL, Diffused Large B Cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. DLBCL, Diffused Large B Cell Lymphoma is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on DLBCL, Diffused Large B Cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

P-CD19CD20-ALLO1 Biological
1 trials
Rimiducid Drug
1 trials

US sites by state

Facility locations filed on DLBCL, Diffused Large B Cell Lymphoma trials. A trial with sites in several states counts in each.

Texas 1 trials
Tennessee 1 trials
South Carolina 1 trials
Pennsylvania 1 trials
Oregon 1 trials
Oklahoma 1 trials
Ohio 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this DLBCL, Diffused Large B Cell Lymphoma page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 DLBCL, Diffused Large B Cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Poseida Therapeutics sponsors the most DLBCL, Diffused Large B Cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See Poseida Therapeutics's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This DLBCL, Diffused Large B Cell Lymphoma condition card totals 1 registered trials; most-linked intervention P-CD19CD20-ALLO1; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.